NXTC CIK: 1661059

NextCure, Inc.

  • United States
  • Healthcare
  • Biotech
Metrics score locked — part of Premium
FY21
FY22
FY23
FY24
FY25
FY21 – FY25
(positive)
millions USD
FY21:
–
FY22:
–
FY23:
–
FY24:
0
FY25:
–
(positive)
Change from FY21 to FY25
millions USD
FY21:
−70.8
FY22:
−75.9
FY23:
−67.6
FY24:
−59.7
FY25:
−57.6
(positive)
Change from FY21 to FY25
millions USD
FY21:
−66.6
FY22:
−71.8
FY23:
−64.0
FY24:
–
FY25:
−55.4
(positive)
Change from FY21 to FY25
millions USD
FY21:
−69.4
FY22:
−74.7
FY23:
−62.7
FY24:
–
FY25:
−55.8
(positive)
Change from FY21 to FY25
millions USD
FY21:
−69.4
FY22:
−74.7
FY23:
−62.7
FY24:
−55.7
FY25:
−55.8

All amounts in millions USD Data sources:SEC EDGARTwelve Data